# A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06190886/  
OnCo record `nct06190886` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of PTX-912 run by Proviva Therapeutics, Inc., now recruiting.

## Summary

A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors is a phase 1 interventional study registered as NCT06190886 by Proviva Therapeutics, Inc., with 26 participants planned, started 2024-06-11, primary completion expected 2026-05-14. Conditions recorded: Advanced Cancer, Solid Tumor, Metastatic Cancer. Interventions recorded: PTX-912.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06190886
- Phase: 1
- Setting: A First-in-human (FIH), Multicenter, Open-Label, Phase Ia (Dose Escalation)/Phase Ib (Dose Expansion) Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
- Sponsor: Proviva Therapeutics, Inc.
- Enrolled: 26

## Sources

- ClinicalTrials.gov NCT06190886: https://clinicaltrials.gov/study/NCT06190886

## Connected records

- drugs: [PTX-912](https://onco.cc/drugs/ptx-912/)
- companies: [Proviva Therapeutics](https://onco.cc/companies/proviva-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06190886.json